ImmunityBio Inc.

AI Score

XX

Unlock

3.04
-0.10 (-3.18%)
At close: Mar 31, 2025, 3:38 PM

ImmunityBio Statistics

Share Statistics

ImmunityBio has 853.44M shares outstanding. The number of shares has increased by 8.34% in one year.

Shares Outstanding 853.44M
Shares Change (YoY) 8.34%
Shares Change (QoQ) 4.83%
Owned by Institutions (%) 11.87%
Shares Floating 88.78M
Failed to Deliver (FTD) Shares 73.57K
FTD / Avg. Volume 1.2%

Short Selling Information

The latest short interest is 54.54M, so 7.47% of the outstanding shares have been sold short.

Short Interest 54.54M
Short % of Shares Out 7.47%
Short % of Float 71.83%
Short Ratio (days to cover) 9.56

Valuation Ratios

The PE ratio is -4.32 and the forward PE ratio is -7.33. ImmunityBio's PEG ratio is 0.09.

PE Ratio -4.32
Forward PE -7.33
PS Ratio 121.07
Forward PS 1.1
PB Ratio -3.66
P/FCF Ratio -4.48
PEG Ratio 0.09
Financial Ratio History

Enterprise Valuation

ImmunityBio Inc. has an Enterprise Value (EV) of 3.17B.

EV / Earnings -7.67
EV / Sales 215.09
EV / EBITDA -11.99
EV / EBIT -9.21
EV / FCF -7.97

Financial Position

The company has a current ratio of 3.36, with a Debt / Equity ratio of -0.09.

Current Ratio 3.36
Quick Ratio 3.21
Debt / Equity -0.09
Total Debt / Capitalization -9.49
Cash Flow / Debt -9.25
Interest Coverage -2.61

Financial Efficiency

Return on equity (ROE) is 0.85% and return on capital (ROIC) is 77.37%.

Return on Equity (ROE) 0.85%
Return on Assets (ROA) -1.08%
Return on Capital (ROIC) 77.37%
Revenue Per Employee $21,683.82
Profits Per Employee $-608,182.35
Employee Count 680
Asset Turnover 0.04
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -41.9% in the last 52 weeks. The beta is -0.18, so ImmunityBio's price volatility has been lower than the market average.

Beta -0.18
52-Week Price Change -41.9%
50-Day Moving Average 3.12
200-Day Moving Average 4.13
Relative Strength Index (RSI) 54.11
Average Volume (20 Days) 6.12M

Income Statement

In the last 12 months, ImmunityBio had revenue of 14.74M and earned -413.56M in profits. Earnings per share was -0.59.

Revenue 14.74M
Gross Profit 14.74M
Operating Income -344.18M
Net Income -413.56M
EBITDA -264.43M
EBIT -344.18M
Earnings Per Share (EPS) -0.59
Full Income Statement

Balance Sheet

The company has 143.43M in cash and 42.29M in debt, giving a net cash position of 101.14M.

Cash & Cash Equivalents 143.43M
Total Debt 42.29M
Net Cash 101.14M
Retained Earnings -3.38B
Total Assets 382.93M
Working Capital 94.86M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -391.24M and capital expenditures -6.89M, giving a free cash flow of -398.12M.

Operating Cash Flow -391.24M
Capital Expenditures -6.89M
Free Cash Flow -398.12M
FCF Per Share -0.57
Full Cash Flow Statement

Margins

Gross margin is 100%, with operating and profit margins of -2.33K% and -2.8K%.

Gross Margin 100%
Operating Margin -2.33K%
Pretax Margin -2.8K%
Profit Margin -2.8K%
EBITDA Margin -1.79K%
EBIT Margin -2.33K%
FCF Margin -2.7K%

Dividends & Yields

IBRX does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -18.91%
FCF Yield -14.93%
Dividend Details

Analyst Forecast

The average price target for IBRX is $8, which is 156.4% higher than the current price. The consensus rating is "Buy".

Price Target $8
Price Target Difference 156.4%
Analyst Consensus Buy
Analyst Count 5
Stock Forecasts

Scores

Altman Z-Score -12.46
Piotroski F-Score 4